# Delivery targets and therapeutic targets

Source: https://onco.cc/terms/delivery-target-versus-therapeutic-target/  
OnCo record `delivery-target-versus-therapeutic-target` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The molecule used to deliver an intervention to a cell can differ from the target of the treatment that cell produces. Both targeting steps need to be named.

## Summary

A primary mouse cardiac-fibrosis study used CD5-targeted lipid nanoparticles to deliver RNA encoding a receptor directed against fibroblast activation protein. CD5 specified a delivery interaction; the encoded receptor had a different recognition target. This is a non-oncology preclinical illustration of the distinction, not cancer-treatment evidence. Delivery, expression, effector recognition and clinical benefit should retain their separate experiments and biological settings.

Targeted-LNP studies show three separate questions. Which cells receive usable cargo: in the CD5 study mRNA reached most cultured mouse T cells (83 per cent expressed the receptor, against 7 per cent with isotype-control particles) and receptor expression appeared across the main T-cell subsets in injured mice, while liver expression occurred with both CD5 and control particles; recombination in a Cre reporter reached 81.1 per cent of CD4-positive and 75.6 per cent of CD8-positive splenocytes but also 15.0 per cent of CD3-negative cells, and the statement that 87 per cent of receptor-positive cells were CD4-positive is a share of expressing cells, not the share of CD4 T cells that expressed the receptor, so each percentage needs its denominator. What the receptor recognises: FDA's January 2024 CAR T guidance says cytokine release and killing should be antigen-dependent, testable with cells that vary in target antigen expression, and asks sponsors to assess targeting of healthy tissue that expresses the intended antigen (on-target, off-tumour) and of other antigens (off-target); activity against antigen-positive healthy cells would therefore show target-dependent activity and a safety concern, not selective cancer killing. Where engineered cells act is a further question: a later study with targeted lipid nanoparticles reports reprogrammed CD8-positive T cells from healthy donors and autoimmune patients, tumour control in humanised mice and B-cell depletion in cynomolgus monkeys, each a different experiment and setting (Hunter and colleagues; abstract only). For a vaccine the address can instead be an antigen-presenting cell: intravenous RNA-lipoplexes were aimed at dendritic cells and macrophages in lymphoid compartments by adjusting net charge, without a molecular ligand (Kranz and colleagues).

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: delivery targeting versus cancer targeting; delivery receptor versus effector target

## Notes

- Separate delivery-marker binding, uptake, expression, receptor engagement, signalling and target-cell effects. A comparison needs identified live-cell populations and matched antigen-positive and antigen-negative controls. A small amount of unintended-cell expression in a sample cannot establish absence across all cells or tissues, and selectively engineering one cell population does not remove risk to healthy antigen-positive targets.

## Sources

- CAR T cells produced in vivo to treat cardiac injury.: https://doi.org/10.1126/science.abm0594
- In vivo CAR T cell generation to treat cancer and autoimmune disease.: https://doi.org/10.1126/science.ads8473
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.: https://doi.org/10.1038/nature18300
- Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products: guidance for industry, January 2024: https://www.fda.gov/media/156896/download

## Connected records

- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- terms: [Binders as targeting modules](https://onco.cc/terms/binder-targeting-module/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Messenger RNA construct anatomy](https://onco.cc/terms/mrna-construct-anatomy/)

---
JSON: https://onco.cc/api/v1/entities/delivery-target-versus-therapeutic-target.json